Company Analysis Shin Nippon Biomedical Laboratories, Ltd.
1. Summary
Advantages
- Price (1669 Β₯) is less than fair price (2067.01 Β₯)
- Dividends (5.52%) are higher than the sector average (2.66%).
- The company's current efficiency (ROE=18.34%) is higher than the sector average (ROE=-9.19%)
Disadvantages
- The stock's return over the last year (-8.98%) is lower than the sector average (-0.3484%).
- Current debt level 34.32% has increased over 5 years from 29.36%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Shin Nippon Biomedical Laboratories, Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 3.3% | 2.5% | -1.1% |
| 90 days | 40.2% | -0% | 3.8% |
| 1 year | -9% | -0.3% | 9.6% |
2395 vs Sector: Shin Nippon Biomedical Laboratories, Ltd. has significantly underperformed the "Healthcare" sector by -8.63% over the past year.
2395 vs Market: Shin Nippon Biomedical Laboratories, Ltd. has significantly underperformed the market by -18.54% over the past year.
Stable price: 2395 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 2395 with weekly volatility of -0.1727% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1669 Β₯) is lower than the fair price (2067.01 Β₯).
Price significantly below the fair price: The current price (1669 Β₯) is 23.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (11.55) is lower than that of the sector as a whole (110.66).
P/E vs Market: The company's P/E (11.55) is lower than that of the market as a whole (121.1).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.87) is lower than that of the sector as a whole (70.3).
P/BV vs Market: The company's P/BV (1.87) is lower than that of the market as a whole (88.19).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.42) is lower than that of the sector as a whole (75.01).
P/S vs Market: The company's P/S indicator (2.42) is lower than that of the market as a whole (88.15).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (8.89) is lower than that of the sector as a whole (18.65).
EV/Ebitda vs Market: The company's EV/Ebitda (8.89) is lower than that of the market as a whole (94.73).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 23.38% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (23.38%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (3.56%).
5.4. ROE
ROE vs Sector: The company's ROE (18.34%) is higher than that of the sector as a whole (-9.19%).
ROE vs Market: The company's ROE (18.34%) is higher than that of the market as a whole (7.67%).
5.5. ROA
ROA vs Sector: The company's ROA (8.28%) is higher than that of the sector as a whole (-9.6%).
ROA vs Market: The company's ROA (8.28%) is higher than that of the market as a whole (3.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (18.08%) is higher than that of the sector as a whole (9.09%).
ROIC vs Market: The company's ROIC (18.08%) is higher than that of the market as a whole (8.77%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 5.52% is higher than the average for the sector '2.66%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 5.52% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 5.52% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (37.47%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
